DCTPep ID  DCTPep01306

Peptide Name   Sequence 2 from Patent US 20100279918

Sequence  CPGPEGAGC

Sequence Length  9

UniProt ID  Q9JJG0  A2VEC9  P98167  Q700K0  Q8CG65 

PubChem CID  Not available

Origin  Synthetic construct

Type  Synthetic peptide

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

PDB ID  Not available

Predicted Structure  Not available

(Please note that there is the predicted structure, predicted by AlphaFold)

Helicity  Not available

Linear/Cyclic  Cyclic

Disulfide/Other Bond  Cys1<--->Cys13

N-terminal Modification  Not available

C-terminal Modification  Not available

Other Modification  None

Chiral  L

Grand average of hydropathicity (GRAVY)  -0.122

Half Life 
  1.2 hours (mammalian reticulocytes, in vitro).
  >20 hours (yeast, in vivo).
  >10 hours (Escherichia coli, in vivo).

Extinction coefficients 
  Ext. coefficient 125
  Abs 0.1% (=1 g/l) 0.158, assuming all pairs of Cys residues form cystines
  Ext. coefficient 0
  Abs 0.1% (=1 g/l) 0.000, assuming all Cys residues are reduced

Amino acid distribution

Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 2010/0279918 A1

Patent Title  Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents.

Other Iinformation  Granted Patent Family: 7s / 7ex; Family Jurisdictions: DE, EP, WO, AT, US; Legal Status: Discontinued; Application No: 22536707; Filed:Mar 20, 2007; Published: Nov 4, 2010; Earliest Priority: Mar 20, 2006;

Other Published ID  DE602007011901D1  EP1991586A1  EP1991586B1  WO2007108749A1  WO2007108749A8